<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>WBC Disorders, Transfusions, and Medications</title>
    <link href="https://fonts.googleapis.comcom/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\(', '\)']],
            displayMath: [['$$', '$$'], ['\[', '\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams' // Use AMS numbering of equations
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="hematology-lymphoid-malignancies.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 100%;"></div> <!-- Set percentage dynamically -->
                        </div>
                       <span class="progress-text">Lecture 6 of 6</span> <!-- Update text -->
                    </div>
                    <a href="#" class="nav-button disabled"> <!-- Add 'disabled' class if last chunk -->
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">WBC Disorders, Transfusions, and Medications</h1>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">
                <!-- START: wbc-disorders -->
                <section id="wbc-disorders" class="content-section" aria-labelledby="section-heading-1">
                    <h2 id="section-heading-1" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">WBC DISORDERS</span>
                    </h2>
                    <div class="content-card">
                        <h3 class="subsection-heading">NEUTROPHILIA</h3>
                        <h4>Definition</h4>
                        <ul>
                            <li>absolute neutrophil count (ANC) >7.5 x 10<sup>9</sup> /liter</li>
                        </ul>
                        <h4>Mechanism</h4>
                        <ul>
                            <li>increased mitosis/proliferation e.g. response to chronic infection</li>
                            <li>decreased marrow storage pool e.g. acute response to infection</li>
                            <li>decreased marginal pool e.g. acute response to infection</li>
                            <li>decreased egress from circulating pool e.g. chronic steroids</li>
                        </ul>
                        <h4>Etiology</h4>
                        <ul>
                            <li>acute infections especially bacterial</li>
                            <li>inflammation</li>
                            <li>metabolic derangement e.g. uremia, acidosis, gout</li>
                            <li>acute hemorrhage or hemolysis</li>
                            <li>malignant neoplasm and myeloproliferative disorders</li>
                            <li>steroid therapy (due to poor migration)</li>
                        </ul>

                        <h3 class="subsection-heading">LEUKEMOID REACTIONS</h3>
                        <ul>
                            <li>blood findings resembling those seen in certain types of leukemia with immature WBC in the peripheral blood film</li>
                            <li><strong>myeloid leukemia mimicked by</strong>
                                <ul>
                                    <li>pneumonia</li>
                                    <li>other acute bacterial infections</li>
                                    <li>intoxications</li>
                                    <li>burns</li>
                                    <li>malignant disease</li>
                                    <li>severe hemorrhage or hemolysis</li>
                                </ul>
                            </li>
                            <li><strong>lymphoid leukemia mimics (see Infectious Diseases Chapter)</strong>
                                <ul>
                                    <li>pertussis</li>
                                    <li>TB</li>
                                    <li>infectious mononucleosis</li>
                                </ul>
                            </li>
                            <li><strong>monocytic leukemia mimics</strong>
                                <ul><li>TB</li></ul>
                            </li>
                        </ul>

                        <h3 class="subsection-heading">NEUTROPENIA</h3>
                        <h4>Definition</h4>
                        <ul>
                            <li>ANC &lt;2.5 x 10<sup>9</sup>/liter</li>
                        </ul>
                        <h4>Mechanisms</h4>
                        <ul>
                            <li>decreased stem cells e.g. aplastic anemia</li>
                            <li>decreased mitosis e.g. marrow hypoplasia secondary to alkylating agents</li>
                            <li>increased ineffective mitosis eg. megaloblastic anemia</li>
                            <li>increased peripheral destruction e.g. hypersplenism</li>
                            <li>combinations e.g. lymphoma</li>
                            <li>increased marginal pool or decreased storage pool egress e.g. viremia</li>
                        </ul>
                        <h4>Etiology</h4>
                        <ul>
                            <li><strong>overwhelming infection</strong>
                                <ul>
                                    <li>viral: HIV, hepatitis, EBV</li>
                                    <li>bacterial: typhoid, miliary TB</li>
                                </ul>
                            </li>
                            <li><strong>drugs and chemicals</strong>
                                <ul>
                                    <li>examples: ionizing radiation, benzene, chemotherapeutic drugs, anti-inflammatory drugs</li>
                                    <li>dose-dependent predictable e.g. anticonvulsants</li>
                                    <li>dose-dependent idiosyncratic e.g. ASA, phenothiazine, indomethacin</li>
                                    <li>dose-independent hypersensitivity</li>
                                    <li>antibody-mediated eg. penicillins</li>
                                </ul>
                            </li>
                            <li><strong>marrow disease</strong>
                                <ul>
                                    <li>low B12/folate</li>
                                    <li>bone marrow infiltration (hematologic malignancies > solid tumours)</li>
                                    <li>aplastic anemia</li>
                                </ul>
                            </li>
                            <li>hereditary: cyclic neutropenia</li>
                            <li>hypersplenism</li>
                        </ul>
                        <h4>Clinical Features</h4>
                        <ul>
                            <li>fever, chills</li>
                            <li>infection by opportunistic organisms</li>
                            <li>painful ulceration on skin, anus, mouth and throat by opportunistic organisms</li>
                            <li>septicemia in later stage</li>
                        </ul>
                        <h4>Diagnosis</h4>
                        <ul>
                            <li>CBC</li>
                            <li>bone marrow biopsy to rule out marrow failure</li>
                        </ul>

                        <h3 class="subsection-heading">AGRANULOCYTOSIS</h3>
                        <p>virtually complete disappearance of granulocytes from the blood and granulocyte precursors from the marrow; drugs often implicated abrupt onset of</p>
                        <ul>
                            <li>fever, chills and weakness</li>
                            <li>oropharyngeal ulcers</li>
                        </ul>
                        <p>drug induced (eg. clozapine) highly lethal without vigorous treatment</p>
                        <h4>Management</h4>
                        <ul>
                            <li>discontinue offending drug</li>
                            <li>antimicrobial therapy e.g. TMP-SMX, ciprofloxacin, antifungal</li>
                            <li>Filgrastim (G-CSF) - growth factor that stimulates neutrophil production</li>
                        </ul>
                    </div>
                </section>
                <!-- END: wbc-disorders -->

                <!-- START: splenomegaly -->
                <section id="splenomegaly" class="content-section" aria-labelledby="section-heading-2">
                    <h2 id="section-heading-2" class="section-heading">
                         <span class="heading-icon"> </span>
                         <span class="heading-text">APPROACH TO SPLENOMEGALY</span>
                    </h2>
                    <div class="content-card">
                        <h3 class="subsection-heading">Etiology</h3>
                        <ul>
                            <li><strong>infections</strong>
                                <ul><li>subacute bacterial endocarditis, TB, salmonella, EBV, CMV, histoplasmosis, malaria, toxoplasmosis, schistosomiasis, HIV/AIDS</li></ul>
                            </li>
                            <li><strong>hematologic disorders</strong>
                                <ul><li>hemolytic anemia, hemoglobinopathies, Fe deficiency anemia</li></ul>
                            </li>
                            <li><strong>congestive splenomegaly, portal hypertension: secondary</strong>
                                <ul>
                                    <li>secondary to portal or splenic vein obstruction</li>
                                    <li>secondary to intrahepatic disease</li>
                                    <li>secondary to CHF</li>
                                </ul>
                            </li>
                            <li><strong>infiltrative or metabolic diseases</strong>
                                <ul><li>lipid storage disease, mucopolysaccharidosis, glycogen storage disease, amyloidosis, tyrosinemia</li></ul>
                            </li>
                            <li><strong>immunological</strong>
                                <ul><li>SLE, sarcoidosis</li></ul>
                            </li>
                            <li><strong>neoplastic</strong>
                                <ul><li>leukemia, lymphoma, Hodgkin's disease</li></ul>
                            </li>
                            <li>epidermal cysts</li>
                            <li><strong>other</strong>
                                <ul><li>serum sickness, Felty's syndrome, osteoperosis</li></ul>
                            </li>
                        </ul>
                        <h3 class="subsection-heading">Mild Spleen Enlargement</h3>
                        <p>0-4 cm below costal margin</p>
                        <p>CHF, SBE, SLE, RA, thalassemia minor, acute malaria, typhoid fever</p>
                        <h3 class="subsection-heading">Moderate Spleen Enlargement</h3>
                        <p>4-8 cm below costal margin</p>
                        <p>hepatitis, cirrhosis, lymphomas, infectious mononucleosis, hemolytic anemias, splenic infarct, splenic abscess, amyloidosis, acute leukemias, hemolytic anemias</p>
                        <h3 class="subsection-heading">Massive Spleen Enlargement</h3>
                        <p>>8 cm below costal margin</p>
                        <p>chronic leukemias, lymphoma, myelofibrosis, hairy cell leukemia, leishmaniasis, portal vein obstruction, polycythemia vera (end-stage), primary thrombocythemia, lipid-storage disease, sarcoidosis, thalassemia major</p>
                    </div>
                </section>
                <!-- END: splenomegaly -->

                <!-- START: transfusions -->
                <section id="transfusions" class="content-section" aria-labelledby="section-heading-3">
                    <h2 id="section-heading-3" class="section-heading">
                         <span class="heading-icon"> </span>
                         <span class="heading-text">BLOOD PRODUCTS AND TRANSFUSIONS</span>
                    </h2>
                    <div class="content-card">
                        <h3 class="subsection-heading">BLOOD GROUPS</h3>
                        <div class="table-container">
                            <table class="content-table">
                                <caption>Table 15. Blood Groups</caption>
                                <thead>
                                    <tr><th>Group</th><th>Antigen</th><th>Antibody</th></tr>
                                </thead>
                                <tbody>
                                    <tr><td>O</td><td>H</td><td>anti-A, anti-B</td></tr>
                                    <tr><td>A</td><td>A</td><td>anti-B</td></tr>
                                    <tr><td>B</td><td>B</td><td>anti-A</td></tr>
                                    <tr><td>A B</td><td>A and B</td><td>nil</td></tr>
                                </tbody>
                            </table>
                        </div>
                        <p>group compatible uncrossmatched blood is safer than O-negative uncrossmatched blood - there is no universal donor</p>
                        <h3 class="subsection-heading">RED CELLS</h3>
                        <div class="table-container">
                             <table class="content-table">
                                <caption>Table 16. Red Cells</caption>
                                <thead>
                                    <tr><th>Product</th><th>Indication</th></tr>
                                </thead>
                                <tbody>
                                    <tr><td>Packed Cells</td><td>symptomatic anemia<br>bleeding with hypovolemia</td></tr>
                                    <tr><td>Frozen Red Cells</td><td>rare blood groups<br>multiple alloantibodies</td></tr>
                                </tbody>
                            </table>
                        </div>
                        <h4>Packed Cells</h4>
                        <ul>
                            <li>stored at 4°C</li>
                            <li>transfuse within 35 days of collection, otherwise hyperkalemia due to cell lysis</li>
                            <li>transfuse within 7 days of collection if renal failure or hepatic failure is present to reduce solute load</li>
                            <li>each unit will raise hematocrit by about 4% or hemoglobin by 10 gm/L (1 g/dL)</li>
                        </ul>
                        <h4>Selection of Red Cells for Transfusion</h4>
                        <ul>
                            <li>donor blood should be crossmatch compatible (by mixing recipient serum with donor RBC)</li>
                            <li>donor blood should be free of irregular blood group antibodies</li>
                            <li>the donor blood should be the same ABO and Rh group as the recipient</li>
                        </ul>
                        <h3 class="subsection-heading">PLATELETS</h3>
                         <div class="table-container">
                             <table class="content-table">
                                <caption>Table 17. Platelet Products</caption>
                                <thead>
                                    <tr><th>Product</th><th>Indication</th></tr>
                                </thead>
                                <tbody>
                                    <tr><td>Random Donor (pooled)</td><td>thrombocytopenia with bleeding</td></tr>
                                    <tr><td>Single Donor Platelets</td><td>potential BMT recipients</td></tr>
                                    <tr><td>HLA Matched Platelets</td><td>refractoriness to pooled or single donor platelets</td></tr>
                                </tbody>
                            </table>
                        </div>
                        <ul>
                            <li>each unit of random donor platelets should increase the platelet count by approximately 10 x 10<sup>9</sup>/L</li>
                            <li>single donor platelets should increase the platelet count by 40-60 x 10<sup>9</sup>/L</li>
                            <li>if an increment in the platelet count is not seen, alloantibodies, bleeding, sepsis or hypersplenism may be present</li>
                        </ul>
                        <h3 class="subsection-heading">COAGULATION FACTORS</h3>
                        <div class="table-container">
                             <table class="content-table">
                                <caption>Table 18. Coagulation Factor Products</caption>
                                <thead>
                                    <tr><th>Product</th><th>Indication</th></tr>
                                </thead>
                                <tbody>
                                    <tr><td>Fresh Frozen Plasma</td><td>Depletion of multiple coagulation factors</td></tr>
                                    <tr><td>Cryoprecipitate</td><td>Factor VIII deficiency<br>Von Willebrand's disease<br>Hypofibrinogenemia<br>Hemate P</td></tr>
                                    <tr><td>Factor VIII Concentrate</td><td>Factor VIII deficiency</td></tr>
                                    <tr><td>Factor IX Concentrate</td><td>Factor IX deficiency</td></tr>
                                </tbody>
                            </table>
                        </div>
                        <h4>Special Considerations</h4>
                        <ul>
                            <li><strong>irradiated blood products</strong>
                                <ul>
                                    <li>potential BMT recipients</li>
                                    <li>immunocompromised patients</li>
                                </ul>
                            </li>
                            <li><strong>CMV negative blood products</strong>
                                <ul>
                                    <li>potential transplant recipients</li>
                                    <li>neonates</li>
                                </ul>
                            </li>
                        </ul>
                        <h3 class="subsection-heading">GROUP AND RESERVE SERUM</h3>
                        <p>an alternative to holding crossmatched blood for individuals who may require transfusion</p>
                        <ul>
                            <li>recipient's ABO and Rh group is determined</li>
                            <li>recipient's serum is tested for the presence of irregular blood group antibodies</li>
                            <li>serum is kept frozen</li>
                        </ul>
                        <p>compatible blood can be issued immediately in an emergency or within 30 minutes electively</p>

                        <h3 class="subsection-heading">ACUTE COMPLICATIONS OF BLOOD TRANSFUSIONS</h3>
                        <h4>Febrile Nonhemolytic Transfusion Reactions</h4>
                        <ul>
                            <li>due to antibodies stimulated by previous transfusions or pregnancies against antigens on donor lymphocytes, granulocytes, platelets or to lymphokines that are released with storage of the cells</li>
                            <li><strong>signs and symptoms:</strong> chills, fever</li>
                            <li><strong>management and prevention</strong>
                                <ul>
                                    <li>stop transfusion</li>
                                    <li>acetaminophen</li>
                                    <li>steroids</li>
                                    <li>filtered blood</li>
                                    <li>washed blood</li>
                                </ul>
                            </li>
                        </ul>
                        <h4>Allergic Reactions</h4>
                        <ul>
                            <li>usually due to interaction between donor plasma proteins and recipient IgE antibodies</li>
                            <li><strong>signs and symptoms:</strong> a spectrum from urticaria and generalized itching to wheezing to anaphylaxis
                                <ul><li>Note: anaphylaxis is rare, usually in IgA deficient patients reacting against IgA in donor plasma</li></ul>
                            </li>
                            <li><strong>management and prevention</strong>
                                <ul>
                                    <li>antihistamines</li>
                                    <li>slow infusion</li>
                                    <li>steroids</li>
                                    <li>washed blood</li>
                                    <li>anaphylaxis may require IV epinephrine and IgA deficient blood components in future</li>
                                </ul>
                            </li>
                        </ul>
                        <h4>Acute Hemolytic Transfusion Reactions</h4>
                        <ul>
                            <li>most commonly due to incorrect patient identification</li>
                            <li>intravascular hemolytic reaction due to complement activation</li>
                            <li><strong>signs and symptoms</strong>
                                <ul>
                                    <li>muscle pain, back pain</li>
                                    <li>fever, N/V, chest pain, wheezing</li>
                                    <li>dyspnea, tachypnea (acute respiratory distress syndrome)</li>
                                    <li>feeling of impending doom</li>
                                    <li>hemoglobinemia</li>
                                    <li>renal failure - DIC</li>
                                    <li>hypotension and vascular collapse</li>
                                    <li>patient under general anesthetic may present with bleeding</li>
                                </ul>
                            </li>
                             <li><strong>investigations</strong>
                                <ul>
                                    <li>repeat crossmatch and donor and recipient blood groups</li>
                                    <li>direct antiglobulin test (direct Coombs' test)</li>
                                </ul>
                            </li>
                            <li><strong>management</strong>
                                <ul>
                                    <li>stop transfusion</li>
                                    <li>hydrate aggressively</li>
                                    <li>transfuse with compatible blood products</li>
                                </ul>
                            </li>
                        </ul>
                        <h4>Citrate Toxicity</h4>
                        <ul>
                            <li>seen with massive transfusion and with liver disease</li>
                            <li>toxicity secondary to hypocalcemia</li>
                            <li>prevented by giving 10 mL of 10% calcium gluconate for every 2 units of blood</li>
                        </ul>
                        <h4>Hyperkalemia</h4>
                        <h4>Circulatory Overload</h4>
                        <ul>
                            <li>signs: dyspnea, orthopnea, cynasosis, sudden anxiety, hemoptysis, crackles in lung bases</li>
                            <li>with prior CHF and in elderly patients</li>
                            <li>minimize the amount of saline given with the blood</li>
                        </ul>
                        <h4>Hemorrhagic State due to Dilutional Coagulopathy</h4>
                        <ul>
                            <li>with massive transfusion</li>
                            <li>packed cells contain no Factor VIII or V or platelets</li>
                            <li>correct with fresh frozen plasma and platelets</li>
                        </ul>
                        <h4>Bacterial Infections</h4>
                        <ul>
                            <li>never give blood >4 hours after a bag has been entered!</li>
                            <li>signs and symptoms: chills, rigors, fever, hypotension, shock, DIC (profound symptoms with Gram negatives)</li>
                            <li>management: blood cultures, IV antibiotics, fluids</li>
                        </ul>
                        <h3 class="subsection-heading">DELAYED COMPLICATIONS IN TRANSFUSIONS</h3>
                        <ul>
                            <li>days to weeks</li>
                            <li><strong>viral infection risks</strong>
                                <ul>
                                    <li>HIV < 1:500,000</li>
                                    <li>HBV < 1:250 ,000</li>
                                    <li>HCV < 1:10,000</li>
                                </ul>
                            </li>
                        </ul>
                        <h4>Delayed Hemolytic Transfusion Reaction</h4>
                        <ul>
                            <li>may be delayed up to 5 to 10 days</li>
                            <li>extravascular hemolysis due to alloantibodies that are too weak to be detected by indirect antiglobulin test or by crossmatch</li>
                            <li>may be confused with autoimmune hemolytic anemia</li>
                            <li>signs and symptoms: anemia, fever, history of recent transfusion, jaundice, positive direct Coombs' test</li>
                            <li>further transfusion should be avoided</li>
                        </ul>
                        <h4>Iron Overload</h4>
                        <ul>
                            <li>often with repeated transfusion for long periods of time, e.g. beta-thalassemia major</li>
                            <li>use of iron chelators after transfusion can reduce the chance of iron overload</li>
                            <li>complications include secondary hemochromatosis
                                <ul>
                                    <li>dilated cardiomyopathy</li>
                                    <li>cirrhosis</li>
                                    <li>DM, hypothyroidism, delayed growth and puberty</li>
                                </ul>
                            </li>
                        </ul>
                        <h4>Transfusion Associated GVHD</h4>
                        <ul>
                            <li>transfused T-lymphocytes recognize and react against the "host" (recipient) between 4-30 days later</li>
                            <li>most patients with this have severely impaired immune systems (e.g. Hodgkin's, NHL, acute leukemias)</li>
                            <li>signs and symptoms: fever, diarrhea, liver function abnormalities, pancytopenia</li>
                            <li>mortality about 90%</li>
                            <li>prevention: gamma irradiation of blood components</li>
                        </ul>
                    </div>
                </section>
                <!-- END: transfusions -->

                <!-- START: medications -->
                <section id="medications" class="content-section" aria-labelledby="section-heading-4">
                    <h2 id="section-heading-4" class="section-heading">
                         <span class="heading-icon"> </span>
                         <span class="heading-text">MEDICATIONS COMMONLY USED IN HEMATOLOGY</span>
                    </h2>
                    <div class="content-card">
                         <div class="table-container">
                             <table class="content-table">
                                <caption>Table 19. Drugs for Anemia</caption>
                                <thead>
                                    <tr><th>Drug</th><th>Common Formulary</th><th>Mechanism of Action</th><th>Clinical Uses</th><th>Common Side Effects</th><th>Contraindications</th></tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>iron</td>
                                        <td>iron gluconate<br>iron sulphate<br>iron fumarate</td>
                                        <td>- for synthesis of hemoglobin</td>
                                        <td>- iron deficiency anemia treatment and prevention<br>- pregnancy</td>
                                        <td>- in children: acute iron toxicity as<br>- necrotizing enterocolitis<br>- shock<br>- metabolic acidosis<br>- coma and death</td>
                                        <td>- iron overload</td>
                                    </tr>
                                    <tr>
                                        <td>B12</td>
                                        <td>cyanocobalamin<br>hydroxycobalamin</td>
                                        <td>- synthesis of folic acid and DNA</td>
                                        <td>- B12 deficiency</td>
                                        <td>- no significant toxicity</td>
                                        <td>- N/A</td>
                                    </tr>
                                    <tr>
                                        <td>folic acid</td>
                                        <td>folic acid</td>
                                        <td>- synthesis of purines and thymidylate thus DNA</td>
                                        <td>- folic acid deficiency<br>- pregnancy</td>
                                        <td>- no significant toxicity</td>
                                        <td>- N/A</td>
                                    </tr>
                                    <tr>
                                        <td>erythropoietin</td>
                                        <td>Epo</td>
                                        <td>- stimulate RBC synthesis</td>
                                        <td>- renal failure<br>- marrow failure<br>- myelodysplastic syndrome<br>- autologous blood donation</td>
                                        <td>- no significant toxicity</td>
                                        <td>- N/A</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                        <div class="table-container">
                             <table class="content-table">
                                <caption>Table 20. Chemotherapeutic Agents</caption>
                                <thead>
                                    <tr><th>Class</th><th>Example</th><th>Mechanism of Action</th><th>Common Toxicity</th><th>Examples of Clinical Use</th></tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>alkylating agent</td>
                                        <td>- nitrogen mustard<br>- cyclophosphamide<br>- nitrosurea<br>- busulfan<br>- cisplatin</td>
                                        <td>- cell cycle non-specific drugs<br>- via alkylation of nucleophilic groups in base pairs<br>- leading to cross-linking of bases or abnormal basepairing or DNA breakage</td>
                                        <td>- marrow suppression<br>- GI irritation<br>- change in gonadal function<br>- nitrogen mustard (cyclophosphamide): hemorrhagic cystitis<br>- busulfan: adrenal insufficiency and pulmonary fibrosis</td>
                                        <td>- cyclophosphamide<br>- breast CA<br>- small cell lung CA<br>- NHL<br>- busulfan<br>- CML<br>- cisplatin<br>- advanced ovarian CA<br>- testicular CA</td>
                                    </tr>
                                    <tr>
                                        <td>antimetabolites</td>
                                        <td>- folic acid antagonist (methotrexate)<br>- purine antagonist (mercaptopurine)<br>- pyrimidine antagonist (5-FU)<br>- hydroxyurea</td>
                                        <td>- all are cell cycle specific drugs<br>- all inhibit DNA synthesis<br>- methotrexate inhibits synthesis of tetrahydrofolate<br>- mercaptopurine inhibits purine synthesis<br>- 5-FU inhibits thymidylate synthesis<br>- hydroxyurea inhibits nucleotide reductase</td>
                                        <td>- marrow suppression<br>- oral mucositis<br>- nausea and vomiting</td>
                                        <td>- methotrexate<br>- breast CA<br>- gestational trophoblastic CA<br>- ovarian CA<br>- mercaptopurine<br>- AML<br>- 5-FU<br>- breast CA<br>- GI CA<br>- hepatocellular CA<br>- hydroxyurea<br>- CML</td>
                                    </tr>
                                    <tr>
                                        <td>antibiotics</td>
                                        <td>- anthracyclines (doxorubicin)<br>- bleomycin<br>- mitomycin-C</td>
                                        <td>- anthracycline is cell cycle non-specific; intercalates between basepairs and thus blocks DNA and RNA synthesis<br>- bleomycin is cell cycle specific (G2); produces free radicals leading to DNA breaks and inhibits DNA synthesis<br>- mitomycin-C is cell cycle non-specific; metabolized in liver to alkylating agent</td>
                                        <td>- anthracyclines<br>- marrow suppression<br>- severe alopecia<br>- cardiomyopathies<br>- bleomycin<br>- pulmonary fibrosis<br>- pneumonitis<br>- hypersensitivity<br>- mucocutaneous reactions<br>- mitomycin-C<br>- myelo-suppression<br>- nephrotoxic</td>
                                        <td>- anthracyclines<br>- breast CA<br>- AML<br>- lymphomas<br>- bleomycin<br>- testicular CA<br>- lymphomas<br>- mitomycin-C<br>- GI malignancies</td>
                                    </tr>
                                    <tr>
                                        <td>alkaloids</td>
                                        <td>- vinblastine<br>- vincristine<br>- podophyllotoxin (etoposide)<br>- taxol</td>
                                        <td>- all are cell cycle specific<br>- vincristine and vinblastine inhibit assembly of microtubules therefore mitotic spindles and M phase<br>- podophyllotoxin activates opoisomerase II therefore DNA breaks down<br>- taxol inhibits disassembly of microtubules therefore cells are stuck in M phase</td>
                                        <td>- all have marrow suppression<br>- vincristine and vinblastine<br>- neurotoxic with areflexia, peripheral neuritis and paralytic ileus<br>- taxol<br>- neurotoxic as above</td>
                                        <td>- vincristine and vinblastine<br>- lymphomas<br>- Wilm's tumour<br>- podophyllotoxin<br>- small cell lung CA<br>- prostate CA<br>- testicular CA<br>- taxol<br>- advanced breast CA<br>- ovarian CA</td>
                                    </tr>
                                    <tr>
                                        <td>hormones</td>
                                        <td>- glucocorticoids<br>- tamoxifen<br>- flutamide<br>- aminoglutethimide</td>
                                        <td>- tamoxifen<br>- as a partial E2 antagonist<br>- flutamide: androgen receptor antagonist<br>- aminoglutethimide: aromatase inhibitor in E2 synthesis</td>
                                        <td>- glucocorticoid<br>- refer to Endocrinology under Cushing's syndrome<br>- tamoxifen<br>- menopausal symptoms<br>- long term: retinopathy<br>- aminoglutethimide<br>- menopausal symptoms<br>- skin rashes</td>
                                        <td>- glucocorticoids<br>- CML<br>- lymphomas<br>- tamoxifen<br>- breast CA<br>- flutamide<br>- prostate CA<br>- aminoglutethimide<br>- metastatic breast CA</td>
                                    </tr>
                                     <tr>
                                        <td>others</td>
                                        <td>- carboplatin<br>- mitoxantrone</td>
                                        <td>- carboplatin<br>- DNA binding<br>- mitoxantrone<br>- ?DNA breaks</td>
                                        <td>- carboplatin<br>- myelo-suppression<br>- nausea, vomiting<br>- nephrotoxicity<br>- mitoxantrone<br>- cardiotoxicity<br>- alopecia</td>
                                        <td>- carboplatin<br>- ovarian CA<br>- mitoxantrone<br>- AML<br>- NHL<br>- breast CA<br>- ovarian CA<br>- lung CA</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                    </div>
                </section>
                <!-- END: medications -->
                
                <!-- START: references -->
                <section id="references" class="content-section" aria-labelledby="section-heading-5">
                    <h2 id="section-heading-5" class="section-heading">
                         <span class="heading-icon"> </span>
                         <span class="heading-text">REFERENCES</span>
                    </h2>
                    <div class="content-card">
                       <p>Armitage J.O. Treatment of Non-Hodgkin's lymphoma. 1993. N Engl J Med. 328: 1023-1030.</p>
                        <p>Bataiile R, Harousseua J. Multiple myeloma. 1997. N Engl J Med. 336:1657-64.</p>
                        <p>Castellone DD. Evaluation of Bleeding Disorders. In Saunders Manual of Clinical Laboratory Science. Craig Lehman ED. WB Saunders CO, Philadelphia, PA, 1998.</p>
                        <p>Cohen K, Scadden D.T. Non-Hodgkin's lymphoma: pathogenesis, clinical presentation, and treatment. 2001. Cancer Treat Res. 104:201-03.</p>
                        <p>Heaney M.L., Golde D.W. Myelodysplasia. 1999. N Engl J Med. 340:1649-60.</p>
                        <p>http://cancernet.nci.nih.gov</p>
                        <p>Lowenberg B. Downing J.R., Burnett A. Acute myeloid leukemia. 1999. N Engl J Med. 341:1051-62.</p>
                        <p>Mackie IJ, and Bull HA. Normal haemostasis and it regulation. Blood Rev 3:237, 1989.</p>
                        <p>Mechanisms of severe transfusion reactions. Transfus Clin Biol. 2001 Jun;8(3):278-81.</p>
                        <p>Pui C., Evans W.E. Acute lymphoblastic leukemia. 1998. N Engl J Med. 339:605-15.</p>
                        <p>Rozman C., Montserrat E. Chronic lymphocytic leukemia. 1995. N Engl J Med. 333:1052-57.</p>
                        <p>Sawyers C. Chronic myeloid leukemia. N Engl J Med. 1999. 340:1330-40.</p>
                        <p>The Merck Manual; Section 11, Chapter 133: platelet disorders.</p>
                    </div>
                </section>
                <!-- END: references -->
            </main>

            <!-- Bottom Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="hematology-lymphoid-malignancies.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 100%;"></div> <!-- Set percentage dynamically -->
                        </div>
                       <span class="progress-text">Lecture 6 of 6</span> <!-- Update text -->
                    </div>
                    <a href="#" class="nav-button disabled"> <!-- Add 'disabled' class if last chunk -->
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script>
</body>
</html>